Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients

Anticancer Res. Sep-Oct 1998;18(5B):3797-802.

Abstract

Background: Hematopoietic toxicity of high-dose carboplatin (HD-CBDCA) chemotherapy can be managed effectively with autologous blood cell support, but no conclusive data are available on its neuro- and ototoxicity.

Patients and methods: We determined the neuro- and ototoxicity of HD-CBDCA in 10 patients affected by advanced ovarian cancer. HD-CBDCA was delivered as 24-hour continuous infusion or as 5-day schedules. Each patient underwent an extended clinical and instrumental neurological and otological evaluation before, during and after treatment.

Results: After HD-CBDCA only 1 patient had a clinically-evident peripheral neuropathy, while 3 additional patients had only distal paresthesias. Neurophysiological examination evidenced mild, although diffuse, sensory nerve impairment. Motor nerve impairment was also occasionally observed. All the sensory and motor pathological changes had a favorable course during the follow-up period. Ototoxicity was more severe than neurotoxicity and, in one case it was dose-limiting and audiologic impairment tended to remain constant also in the follow-up period.

Conclusions: HD-CBDCA treatment can be tolerated by most of the patients, but careful monitoring of neuro- and, especially, ototoxicity should be planned.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Carboplatin / administration & dosage*
  • Carboplatin / adverse effects
  • Carboplatin / therapeutic use
  • Female
  • Humans
  • Middle Aged
  • Neurons / drug effects
  • Ovarian Neoplasms / drug therapy*
  • Prognosis

Substances

  • Antineoplastic Agents
  • Carboplatin